Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
Met Non Small Cell Cancer Registry (MOMENT)
NCT05376891 · View on ClinicalTrials.gov ↗
Study Summary
The purpose of this multi-national disease registry is to collect prospectively (with longitudinal follow-up) high-quality, standardized, and contemporaneous data to capture changes in the non-small cell lung cancer (NSCLC) treatment landscape and outcomes over time. The registry will capture data on participants; demographic, clinical characteristics (including biomarker data), treatment patterns, and effectiveness and safety outcomes for advanced NSCLC with mesenchymal-epithelial transition exon 14 (METex14) participants treated with systemic therapy.
Conditions Studied
Study Locations (20)
Other
- Klinikum Klagenfurt Am Woerthersee — Klagenfurt
- Klinik Floridsdorf — Vienna
- AZ Delta — Roeselare
- AZ Nikolaas — Sint-Niklaas
- Ottawa Hospital General Campus — Ottawa
- Princess Margaret Cancer Centre — Toronto
- FN Olomouc — Olomouc
- University Hospital Na Bulovce — Prague
- Centre Hospitalier de Cholet — Cholet
- CHRU Lille — Lille
- Hôpital du Scorff — Lorient
- Centre Leon Berard — Lyon
- Hospital Tenon & University Paris 6 — Paris
- Institut Curie - Centre de Lutte Contre le Cancer (CLCC) — Paris
- CHU de Toulouse Hopital Larrey — Toulouse
- Klinikum Chemnitz GmbH — Chemnitz
- KKH Grosshansdorf GmbH — Großhansdorf
Florida
- Holy Cross Health — Fort Lauderdale
Ohio
- The Ohio State University Wexner Medical Center — Columbus
Tennessee
- Vanderbilt University Medical Center — Nashville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 700 participants |
| Start Date | 2022-10-04 |
| Est. Completion | 2028-04-28 |
Interested in This Trial?
Always speak with your doctor before enrolling in a clinical trial.
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05376891
The ClinicalTrials.gov registry entry for NCT05376891 describes a study currently listed as recruiting. It is categorized as an unspecified phase, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 700 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is EMD Serono Research & Development Institute, which has 51 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.
The record links to 1 condition, with Cancer appearing as the primary indexed condition, and to 0 interventions. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.
Geographic footprint matters for practical reasons: NCT05376891 reports 20 study locations spanning 4 distinct geographic areas — top geographies include Other, Florida, Ohio. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.
Frequently Asked Questions
What is clinical trial NCT05376891 about?
NCT05376891 is a clinical study titled "Met Non Small Cell Cancer Registry (MOMENT)". The purpose of this multi-national disease registry is to collect prospectively (with longitudinal follow-up) high-quality, standardized, and contemporaneous data to capture changes in the non-small cell lung cancer (NSCLC) treatment landscape and outcomes over time. The registry will capture data ...
What is the current status of trial NCT05376891?
This trial is currently recruiting. The enrollment target is 700 participants. The study started on 2022-10-04. Estimated completion is 2028-04-28.
What conditions does trial NCT05376891 study?
This clinical trial studies the following conditions: Cancer. These conditions were identified from the trial registry and reflect the primary focus areas of the research.
Who is sponsoring clinical trial NCT05376891?
This trial is sponsored by EMD Serono Research & Development Institute, which has 51 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.
Where is trial NCT05376891 being conducted?
This trial has 20 study locations across Florida, Ohio, Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How Clinical Trials Work
Understand phases 1-4, trial design, randomization, and the informed consent process.
Patient Rights in Clinical Trials
Your rights as a participant: consent, withdrawal, privacy, and who to contact.
Finding the Right Clinical Trial
A practical guide to searching trials, understanding eligibility, and evaluating options.
All Guides
Browse our complete library of clinical trial educational resources.
Read our methodology — how this data is sourced, computed, and verified.